Synairgen Plc

Synairgen Plc

Sector: Pharmaceutical Preparations Region: United Kingdom

: | London Stock Exchange: SNG

Similar to: AstraZeneca Plc, Cephalon, Inc., BioGaia AB

Synairgen Plc is a respiratory drug development company with a particular focus on lung antiviral defense in asthma, chronic obstructive pulmonary disease (COPD) and severe viral infections. It is developing inhaled interferon beta 'IFN-ß' in two programmes: to prevent asthma and COPD patients suffering severe exacerbations as a result of cold or flu infections; and to treat other patients who have been hospitalized with severe viral lung infections. Synairgen was founded by Donna E. Davies, Ratko Djukanovic and Stephen T. Holgate in June 2003 and is headquartered in Southampton, the United Kingdom.

News & Analysis

You may also be interested in: